^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC
Excerpt:
...RECIST1.1 radiological response rate following standard treatment with combined chemotherapy with trastuzumab in relapsed or metastatic gastric cancer with positive expression of HER2 in CTC and negative in tumor tissue.`...
Trial ID:
Source:
Title:
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
Excerpt:
...Patients with HER-2 expressing tumors (e.g., ovarian, pancreatic, colon, gastric, endometrial, or breast) with measurable or non-measurable disease for which...
Trial ID:
More C2 evidence
Source:
Title:
Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
Excerpt:
...HER2 expression status was evaluated in primary gastric cancer or metastatic lesion....
Trial ID:
Source:
Title:
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
Excerpt:
...Whole blood pharmacokinetics (PK) of 89Zr-DFO*-trastuzumab (Maximum Plasma Concentration (Cmax) µg/mL)`Whole blood PK of 89Zr-DFO*-trastuzumab (AUC µg/mL × h)`Plasma PK of 89Zr-DFO*-trastuzumab (Cmax in µg/mL)`Plasma PK of 89Zr-DFO*-trastuzumab (AUC µg/mL × h)`Image-derived PK for 89Zr-DFO*-trastuzumab (µg/mL)`Literature-derived PK for unlabelled trastuzumab (Cmax in µg/mL)`Literature-derived PK for unlabelled trastuzumab (AUC in µg/mL × day)`Visual PET imaging analysis of tumor uptake of 89Zr-DFO*-trastuzumab and 89Zr-trastuzumab`Tumor-to-blood ratio of 89Zr-DFO*-trastuzumab (whole blood and plasma as well as image derived)`Tumor-to-image derived blood uptake ratio of 89Zr-trastuzumab`HER2 expression measured by IHC on tumor biopsies...
Trial ID:
Less C2 evidence
Source:
Title:
1481P - Expression of ERBB2 and PD1 mRNA in advanced gastric cancer
Published date:
09/14/2020
Excerpt:
A retrospective cohort of patients (pts) with advanced GC treated...trastuzumab-based chemotherapy (T-chemo)...In pts with HER2+ GC treated with T-chemo, overall response rate (ORR) in ERBB2-low (below median) and ERBB2-high groups was 14.3% and 53.4%, respectively (p=0.046).
Secondary therapy:
Chemotherapy
Source:
Title:
Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy.
Published date:
05/28/2020
Excerpt:
All patients received neoadjuvant therapy with trastuzumab (100%) + chemotherapy: FLOT (2 patients), FOLFOX (7 patients), XELOX (1 patient)....Two patients (20%) maintained the HER2-positive status and six patients (60%) had a change in HER2 expression from positive to negative. Three patients had a (y)pT3 and 5 had a (y)pN+ tumor. Basing on histological changes the tumor regression TRG3 ( < 10% residual tumor cells) was observed in 5 patients (50%). TRG 4-5(preponderance of tumor cells/tumors without changes of regression) observed in 3 patients (30%). The follow-up period is too short for disease-free survival or overall survival to be assessed....HER2 expression can change after trastuzumab-based chemotherapy in patients with locally advanced HER2-positive gastric cancer.
Secondary therapy:
FLOT; FOLFOX; XELOX
DOI:
10.1200/JCO.2020.38.15_suppl.e16529
Source:
Title:
Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients
Published date:
11/26/2019
Excerpt:
Sixty-nine trastuzumab-treated GC patients were enrolled from two different cohorts...In univariate analysis, trastuzumab IHC ≥2+ and HER2 IHC 3+ were only significant predictive factors for OS in trastuzumab-treated patients.
DOI:
10.3390/biom9120782
